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Abstract A recent health economic survey in Europe has
suggested that migraine is the costliest among the neuro-
logical disorders. According to many studies, migraine and
other disorders lead to widespread suffering, reduction of
quality of life, and marked impairment of participation,
both in work and social activities. The present literature
survey was made in order to summarize what is known on
the subject, as a preparation for a EU-supported study to
assess the impact in several EU countries with similar
methodology and the same research instrument. Previous
studies have yielded relatively reliable data only for
migraine, whereas the impact of tension-type headache is
virtually unknown or only very incompletely known for
most dimensions of headache impact. Some data do sug-
gest, however, that this headache may be as important from
a health economic and a public health perspective as
migraine. In future studies it is important to get population-
based data from various countries relevant for estimation of
indirect (mostly absenteeism from work and reduced
working efficiency when having headache) and direct costs
(related to medication, consultations, investigations and
hospitalisations). Also, the impact on ability to get educa-
tion and participate in the workforce is very relevant, as is
the impact on love life and family planning. The quality of
life of headache patients should be measured by validated
instruments. To get a complete picture, one should also ask
about the effect on the life of partners and children, and on
the possible impact even when headache-free (e.g. fear of
the next attack).
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Introduction
For a just and rational distribution of means to health-care
services and health-related research, reliable data on the
individual and societal impact of different disorders are
crucial. In recent years several initiatives have been laun-
ched to raise the awareness that headache is not only a
nuisance for some individuals, but also that it entails
widespread suffering and loss of opportunities for patients
and their families, and large cost for the society. The
recently published report on the prevalence and burden of
headache [1] is a premise for the campaign ‘‘Lifting the
burden: The Global Campaign to reduce the burden of
headache’’[2]. In Europe, much data on both the economic
costs of migraine have been collected and presented in
connection with the ‘‘Cost of Brain Disorders in Europe’’
project [3], in which migraine is treated along with many of
the other (neurological and psychiatric) ‘‘brain disorders’’.
The Eurolight project (http://www.eurolight-online.eu) is
an initiative supported by the EC Public Health Excecutive
Agency launched in May 2007. Its objectives are to
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bring together the relevant medical, scientific and lay
organizations, and to gather updated reliable comparable
information regarding migraine, tension-type and chronic
headache. It will be the first data collection on headaches at
EU level focusing on a holistic, patient-driven and scien-
tifically validated approach, aiming to fill in the main holes
in our knowledge by performing comparable studies on
headache prevalence and its impact in selected European
countries (Austria, France, Germany, Italy, Lithuania, the
Netherlands, Spain, UK, Ireland, Luxembourg). A pilot
study has already been performed in Luxembourg. The
present review of the existing literature on both economic
and non-economic impact was performed as a part of the
Eurolight project, to assess the current state of knowledge,
and to build up a questionnaire to measure all the most
relevant aspects of headache impact. This study presents
the results of this review and a suggestion of the main
dimensions that ought to be covered in the headache impact
tool to be used in the Eurolight study.
Economic impact of headache
Headache may have considerable economic consequences,
both for the patient and for the society as a whole. There
are more studies about the societal costs than about the
individual economic losses of the patients.
Relation to socioeconomic status, education
and employment
In a large Norwegian study (the HUNT study), both
migraine and headache in general was associated with low
socioeconomic status [4], which has also been found in
North America [5, 6] but not in some smaller European
studies [7–11]. The question whether this is a consequence
or a cause of headache is not satisfactorily answered, but in
one Swedish study, half of the patients reported a negative
influence of migraine on their ability to pursue studies and
one third a negative influence on their finances [9]. In a US
study it was found that headache patients have somewhat
reduced labour force participation [12], but employment
status has not been found to be related to headache in some
European studies [7, 13].
Absenteeism from work
In two relatively old studies, one from Finland in 1979 [14]
and one from San Marino in 1986 [15], 7% of working
individuals had been absent from work in the previous year
due headache. In a Danish study of 1992 [16], it was found
that 43% of migraineurs (5% of the population) and 12% of
TTH patients (9% of the population) had been absent from
work during the previous year due to headache, i.e. a total
of 14% of the population. In a Swedish study of 2004 [9], it
was found that 65% of migraineurs reported some degree
of absence from either school or work during the previous
year. These data are, however, of relatively limited interest
from an economical viewpoint as they do not indicate the
number of days that the headache sufferers are away from
work.
The number of days with work absence due to head-
ache is relatively consistent across studies from different
countries. In some previous studies it has varied between
2 and 6 days per year among headache patients in general
[17], and between 1.5 and 4.2 days per year in migrai-
neurs [9]. A study among migraineurs in Sweden revealed
that 35% were never absent from work due to migraine,
and 54% were absent 1–2 days per year [9]. Compared to
headache-free individuals, migraine patients in the HUNT
study from Norway lost on average 4.4 workdays per
year, and persons with non-migrainous headache lost 2.5
workdays per year [18]. In the Danish study from
Copenhagen [16], the TTH patients who had been absent
seem to have been as much or more absent from work
than the migraine patients, and the number of workdays
lost due to migraine was 270 and to TTH 820 per 1,000
persons per year, i.e. a total of 1,090 days. In a study
from England in 2003 [13], 15% had been absent from
work or had reduced ability to work due to headaches in
the previous 3 months. Per year, headache accounted for
1,327 missed and 5,213 reduced ability days per 1,000
workers per year, representing 0.5 and 2.0% of all
working days in the adult population, irrespective of
headache status. This study did not relate absenteeism to
different headache diagnoses. In an English study of
2003, an estimated 5.7 workdays per year was missed by
migraineurs working or attending school [8]. This seems
to be higher than in France where a diary-based regis-
tration of absenteeism published in 1999 showed that
migraineurs were away from work 2.18 days per year due
to headache [19].
Effectiveness when working with headache
Working with migraine results in a 35% productivity loss
on average according to some European studies [20]. This
figure is, however, largely based on migraineurs’ self-
report, which may give a too high estimate according to a
recent US study from a workplace[21]. In this study, it was
found that the working ability assessed by self-report was
much lower than the objectively measured working effi-
ciency (20 vs. 8%). The relatively small decline in working
ability led the authors to conclude that workers with even
relatively severe headache find creative ways to cope with
the pain and maintain standards.
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Health economic studies
For the headache part of the ‘‘Cost of Brain Disorders in
Europe’’ project, a literature search for studies containing
cost data for migraine and other headaches identified eight
European studies evaluating the direct or indirect costs of
migraine from a societal perspective [20], from France
[22, 23], Germany [24], The Netherlands [25], Spain [26],
Sweden [27] and the UK [28, 29]. No studies analysing the
cost of TTH or other non-migraineous headaches were
found. There were large variations in costs across the six
European countries where data were available, ranging
from around €100 per patient per year in Sweden to nearly
€900 in Germany. These variations are probably mostly due
to different methodologies and differences in the year when
the studies were conducted. An important finding was that
the vast majority of total costs, between 72 and 98%, was
indirect costs, due to lost productivity, either in the form of
work absence or reduced efficiency levels when working
with migraine. Women tended to lose more workdays than
men, but indirect costs were similar due to lower salaries
and labour force participation amongst women. The direct
costs, related to consultation, diagnostic investigations,
treatments, and hospital admissions accounted for less than
30% of total costs in most studies.
The cost estimate for migraine in the European report
was based on an average of the most representative cost
estimates, from the UK, Germany and France. An average
annual cost of €585 per migraine patient was estimated for
these Western European countries. The 1-year prevalence
of migraine was 14% among adults in Europe according to
the review of epidemiological studies [1], i.e. 41 million
adult Europeans with active migraine. Per patient migraine
was the least costly disorder among the brain disorders.
However, due to the high prevalence, the total cost of
migraine was estimated to be €27 billion for whole Europe
in 2004, which was the highest cost among the purely
neurological disorders. Many of the psychiatric afflictions
were even more costly according to this review. It is,
however, likely that the available cost data in Europe
would tend to underestimate the actual costs of headache,
mainly because no cost data existed on the most common
headache type (TTH), but also because children and ado-
lescents were not considered, and because cost connected
with more expensive medication (triptans) were not
included, since most cost studies were performed before
this class of drugs was introduced.
In a separate paper summarizing the prevalence and cost
data for headache in Europe [30] a more speculative esti-
mate for the cost of headache, rather than migraine alone,
was derived by using the results of the Danish [31] and
British [32] population-based studies which demonstrated
that around 1,100–1,300 days per 1,000 workers were
missed due to headache each year. The British study also
suggested that the number of days with reduced efficacy
was around four times higher than the number of days
missed. Assuming a reduced efficiency of 35% when
working with headache, and that the direct costs of head-
ache constitute the same proportion of the total costs as for
migraine, the average total cost per headache patient was
estimated to be roughly €420 per year (of which €390
would be due to indirect costs and €30 due to direct
medical costs). Since headache in general was found to
affect nearly 50 % of Europeans, this estimate, if true,
would make headache a much more costly disorder than
migraine alone.
It is of interest to compare the European cost study [3]
with more recent cost studies in some individual European
countries. In one study from Spain [33] the annual costs of
migraine was only about 50% of the sum given in the
European Cost study for the same country. The difference
may partly be explained by somewhat lower prevalence
figures (12 vs. 14%) for migraine used in the Spanish study,
but the main difference may be that this study did not
employ a bottom-up design, but used published statistics
and data to estimate resource use and productivity losses,
which may have led to an underestimation of some costs. A
recent study from France [34], restricted to the direct costs
in 1999, found that these costs were at least twice as high
(€128) as in the European migraine cost study (\€60). This
study included both ‘‘strict’’ migraine (IHS 1.1 and 1.2)
and ‘‘migraineous disorder’’ (IHS 1.7, corresponding to 1.6
in ICHD-2), which together affected 17% of the popula-
tion. For the whole country the direct costs amounted to
more than 1 billion €, which was 0.068% of the gross
national product. Non-migraineous episodic headache,
affecting 9.2% of the population, entailed a considerably
lower cost of €28.
It may also be of interest to compare the European
studies with one US study using a quite different meth-
odology to assess direct costs. In this study, all types of
medical care costs (not only those related to headache)
were derived from the claims records of a large health plan,
whereas diagnostic status (migraine or not) and comorbid
and demographic status was ascertained using a telephone
interview among members of the health plan [35]. Mi-
graineurs incurred on average $700 more per year in total
medical care costs than the controls. Interestingly, this
statistically significant difference disappeared when psy-
chiatric comorbidity variables (anxiety and depression)
were entered into the model. The much higher costs per
patient reflected in this study than in the French study [34]
and Spanish study [33] may therefore at least partly be due
to the differences in cost assessment methodology, indi-
cating that the direct costs specifically related to migraine
and not to comorbid disorders are most reliably assessed by
J Headache Pain (2008) 9:139–146 141
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a direct method, questioning patients about use of health-
care resources.
Medication for headache constitutes an important part of
the direct costs. In France in year 2000, the most frequently
used acute medications for migraine were paracetamol,
salicylates and NSAIDs. Triptans were used by 8% of
migraineurs, and prophylactic treatment was used by 6%
[36]. In Denmark 26% of migraineurs had used triptans in
2001, but less than 5% of those with pure migraine had
used prophylactic medication [37].
Non-economic impact
From a purely humanitarian perspective, but also from a
public health perspective, the pain, suffering and disability
caused by headaches are as important as the economic
consequences. In a study performed in young women in
nine Western European countries, 86% of migraineurs
stated that their life would have been better if they did not
suffer form migraine [38]. A German study showed that, on
average, patients with migraine or TTH had around
1 month every year affected by headaches [10]. The main
burden of headache is carried by a minority of sufferers,
and a Swedish study has shown that 27% of migraine
patients had 68% of all attacks [9]. Three to 4% of the
European population have headache half of the days or
more per month [1].
Disability
It has been calculated that in the US, 300,000 persons stay
in bed each day (24 h) due to headaches [39]. A Swedish
study has shown that the disability is not only related to the
attacks since many migraine patients report an impairment
also between attacks [40]. Nine % of patients report that
they have some residual disability since they do not recover
completely between attacks, and in addition, many patients
live in a constant worry about the next attack [9, 38].
In some studies, the level of disability due to migraine
has been evaluated with the Migraine Disability Assessment
Scale (MIDAS). With this instrument, days with work
absence (job or household chores), days with C50%
reduction in productivity, and days with inability to par-
ticipate in social activities are counted during a 3-month
period. In France, among those with active migraine, 22%
(1.5% of the whole population) had grades III or IV dis-
ability (moderate or severe disability, indicating 11 days or
more during the last 3 months’ period when headache
affected work/household chores 50% or more, or leisure
activities) [36]. MIDAS III or IV were about twice as
common among migraineurs in one US study (54%) [41], as
it was in the multinational Latin American study (50%)
[42]. Among patients with headache in general (both
migraine and non-migraineous headache, comprising 70%
of the study population), 10.3% (7.2% of the population)
had MIDAS grade III or IV disability [13]. Comparing the
percentage of the general population in France with MIDAS
disability grade III–IV due to migraine (1.5%) [36], with the
percentage of population in England with same disability
due to headache in general (7.2%) [13], it seems that non-
migraineous headache causes more disability on a popula-
tion than does migraine. The headache-attributed lost time
(HALT) index is a close derivative of MIDAS (http://www.
liftingtheburden.org/ ? Resources ? Burden measure) to
be used for headache burden studies, which will be con-
ducted by the Lifting The Burden Campaign [43].
According to the World Health Organisation (WHO),
the preferred measure of disease burden is ‘‘Disability
Adjusted Life Years’’ (DALYs), which is a sum of the
years of life lost (YLL) and the years lived with disability
(YLDs). The YLDs are determined by the incidence and
duration of the disorder, and by a disability weight ranging
between 0 and 1 [44]. Although migraine entails no
increased mortality (i.e. YLL = 0), it ranked the 19th
among the leading causes of DALYs among women aged
between 15–44 years, and with regard to YLDs, it was 19th
for both sexes, and the 12th for women, irrespective of age.
Using the WHO data for a calculation of the burden
of ‘‘brain disorders’’ (i.e. the psychiatric and neurological
disorders) in Europe, the weight of migraine was lower
than that of the major psychiatric disorders, dementias,
stroke and injuries, but higher than that of epilepsy, mul-
tiple sclerosis and Parkinson’s disease[45].
In a recent report on the global prevalence and burden of
headache disorders, the burden of migraine and TTH were
measured in a similar way as the DALYs by combining
data on prevalence, mean number and duration of headache
attacks, and headache intensity, from studies containing
such information. For the world as a whole, it was dem-
onstrated that TTH resulted in a higher population burden
(approximately 55% of total burden) than migraine (45%).
The data for Europe indicated an even higher burden due to
TTH compared to migraine [1]. If one uses the European
data from this study it can be calculated that the hours with
migraine headache would add up to between 34 and 100 h
per year, if distributed on each adult individual in the
population. The data on TTH are too scarce to use for
similar calculations.
Studies using validated QoL-instruments
The SF-36 is a validated instrument to measure quality of
life (QoL), containing eight dimensions. One US study
142 J Headache Pain (2008) 9:139–146
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[46], recruiting migraine patients from a medication trial,
demonstrated that migraineurs had lower QoL than the
general US population, most marked for bodily pain,
physical role limitations and social functioning.
A Dutch population-based study found that migraine
had a negative influence on all a dimensions compared
to controls. The negative influence on QoL was larger
than that of e.g. asthma, and it increased with increasing
headache frequency [47]. Two population-based studies
from Spain among chronic daily headache sufferers
showed a marked negative influence, most marked for
those with medication overuse, but similar for those with
a headache of a migraine or a tension type [48]. One of
these showed that the headache frequency may have a
greater impact than headache intensity on QoL [48], and
the other that chronic headache with medication overuse
was associated with a decrease in all QoL aspects
studied with SF-36, most marked for physical role and
bodily pain [49]. A study from UK showed that mi-
graineurs with high or moderate disability had a marked
reduction on all dimensions on the SF-36 [50]. One
Swedish study compared SF-36 results in the two sexes
and in participants with different pain conditions. There
was a gender difference for headache, which in men
influenced physical function, physical role and bodily
pain most, and in women vitality, social functioning,
emotional functioning and mental health [51]. In a
French study, migraineurs had significantly lower scores
than headache-free controls on all SF-36 dimensions, and
lower scores on the pain dimension than those with other
headaches or with TTH [52].
One study comparing migraineurs in the US and the UK
used a shorter QoL instrument, the SF-12, which contains a
physical and a mental component [53]. In both countries,
migraineurs had lower scores than controls on both com-
ponents also after adjusting for socioeconomic status and
for depression. However, in those with both migraine and
depression, the QoL was significantly reduced in compar-
ison to those who were not depressed.
In another French study, using a disease-specific QoL
instrument called QVM, the QoL was found to be lowest
among those with chronic headache, intermediate among
migraineurs and highest among subjects with other forms
of episodic headache [54].
The total burden of headache patients may not only be
related to the headache per se, but also to comorbid con-
ditions. European population-based studies have
demonstrated that depression and/or anxiety occur two to
three times more often among migraineurs than in the
general population [55, 56]. Depression adds to the
reduction in QoL in migraine [53]. This comorbidity may
be as important for non-migrainous headache [57], but it is
not known how this comorbidity influences the QoL in
other headaches. In addition, it has been found that head-
ache is also comorbid with other bodily pain, both in
Finnish children [58] and Norwegian adults [59].
Family impact of migraine
Migraine also affects the patients’ spouses and children. In
a population-based Swedish study [9], the percentage of
migraine sufferers who reported a negative impact of
migraine was 76% for attendance to work, 67% for family
situation, 59% for leisure time, 48% for pursuing studies,
46% for sexual life, 37 % for their social position, 31% for
love, 30% for their financial situation, 27% for making a
career, and 11% for making friends.
One study has measured the impact on the family in
two population samples of similar size in US and UK
[60]. The impact was very similar in both countries. More
than 60% of patients reported a marked impact on the
ability to do household chores because of their migraine
during the past 3 months, and it was markedly reduced
also in 20% of the patients’ partners. Almost 46% of
patients, and 24% of partners had missed days of family
or social activities due to the proband’s migraine, and
16% of patients and 12% of partners had avoided making
plans for family or social activities due to the proband’s
migraine. As to the impact on the children of patients,
more than 60% stated that it had a moderate to marked
influence on the relation with their children, 40% stated
that they would have been a better guardian or parent
without migraine, more than 10% stated that their chil-
dren had missed school, and 10% that their children had
been late to school because of their headache. Forty-six
percent of patients stated that they would have been better
partners without headaches, and 5% stated that they had
had fewer children because of headache, 0.4% that they
had avoided having children, and 15% that they had
avoided oral contraception. Compared with a control
group, the partners of migraine patients were significantly
more dissatisfied with the demands, responsibility and
duties placed upon them, and with their ability to
perform.
Conclusions
Health economic studies have documented that the costs of
headache disorders are huge; the costs only for migraine
amounting to €27 billion in the EU countries, and the cost
for other headaches are probably as large. However, better
population-based cost studies are needed to assess the cost
involved with TTH. Headache sufferers tend to have
lower income and education, and more of them may be
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unemployed, but it is still uncertain whether this is true for
most European countries, and also whether it may be a
cause of or an effect of headache. It is also amply docu-
mented that migraine confers a high degree of disability
with more forced absence from work and leisure activities,
and migraineurs also have a measurably reduced quality of
life. In addition, there is a marked impact on family life,
and headaches also put considerable strains on partners and
children. A minority of headache sufferers chose to have
fewer children than they would have had if they had not
had headaches.
Based on the present review we have identified some
main domains, summarized in the Table 1, that should be
covered in order to capture as much as possible of the
headache burden. The investigations should be performed
in population-based samples, and to assess the whole bur-
den, it is particularly important that not only migraine is
included but also TTH and the chronic headaches. Differ-
ent studies show marked variations between countries, both
with regard to prevalence and burden of headache. At
present it is not possible to determine with certainty whe-
ther these differences are real or due to variations in
methodology. This highlights the need to study several
countries with the same methodology and instrument,
which will be done in the ongoing studies of the Eurolight.
If further research shows that there are real and important
differences between various countries and regions, inves-
tigations to determine the causes of such differences may
elucidate ways to lower the burden of headache in a pop-
ulation. In any case, we believe that the Eurolight studies
will provide the evidence needed to let headache disorders
get the resources for treatment and research that they
deserve according to the burden they place on people in
Europe.
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